Interactions between leptin and insulin resistance in patients with prediabetes, with and without NAFLD

Bungau,Simona; Behl,Tapan; Tit,Delia Mirela; Banica,Florin; Bratu,Ovidiu G.; Diaconu,Camelia C.; Nistor‑Cseppento,Carmen D.; Bustea,Cristiana; Aron,Raluca A. Corb; Vesa,Cosmin Mihai

doi:10.3892/etm.2020.9327

Interactions between leptin and insulin resistance in patients with prediabetes, with and without NAFLD

Authors:
- Simona Bungau
- Tapan Behl
- Delia Mirela Tit
- Florin Banica
- Ovidiu G. Bratu
- Camelia C. Diaconu
- Carmen D. Nistor‑Cseppento
- Cristiana Bustea
- Raluca A. Corb Aron
- Cosmin Mihai Vesa
View Affiliations

Affiliations: Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania, Chitkara College of Pharmacy, Chitkara University, 140401 Punjab, India, Clinical Department 3, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department 5, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Psycho‑Neurosciences and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania, Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania
Published online on: October 14, 2020 https://doi.org/10.3892/etm.2020.9327
Article Number: 197

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study explored the link between insulin sensitivity, insulin resistance and leptinaemia in people with prediabetes with and without non‑alcoholic fatty liver disease (NAFLD). A total of 143 prediabetes patients were evaluated in the study. Ultrasonography was used for diagnosis of NAFLD, and fasting insulin, postprandial insulin, leptin levels, common clinical/biochemical determinations were determined. In total, 69 (48.25%) of the patients were diagnosed with NAFLD and 74 (51.75%) without NAFLD. Leptin values correlated statistically with fasting insulin in prediabetes patients, while in the patients that were also diagnosed with NAFLD the correlation was stronger. Values of log‑leptin <1 ng/ml were found in 64% of patients with prediabetes without NAFLD, and in 2% of patients with prediabetes and NAFLD. In the context of the association between serum leptin levels and a worse biochemical profile in prediabetes patients on one hand, and fatty liver disease and a worse biochemical profile in prediabetes patients on the other, leptin can be considered a possible candidate molecule that mediates the biochemical alterations identified in these patients.

View Figures

View References

1	Caldwell S and Argo C: The natural history of non-alcoholic fatty liver disease. Dig Dis. 28:162–168. 2010.PubMed/NCBI View Article : Google Scholar
2	Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Bermacki D, Orsak B, Subbarayan S, Webb A, Hecht J and Cusi K: High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 100:2231–2238. 2015.PubMed/NCBI View Article : Google Scholar
3	Remus Popa A, Fratila O, Rus M, Corb Aron RA, Mihai Vesa C, Pantis C, Diaconu CC, Bratu O, Bungau S and Nemeth S: Risk factors for adiposity in the urban population and influence on the prevalence of overweight and obesity. Exp Ther Med. 20:129–133. 2020.PubMed/NCBI View Article : Google Scholar
4	Vesa CM, Popa L, Popa AR, Rus M, Zaha AA, Bungau S, Tit DM, Corb Aron RA and Zaha DC: Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics (Basel). 10(314)2020.PubMed/NCBI View Article : Google Scholar
5	Zhou Y and Rui L: Leptin signaling and leptin resistance. Front Med. 7:207–222. 2013.PubMed/NCBI View Article : Google Scholar
6	Ernst MB, Wunderlich CM, Hess S, Paehler M, Mesaros A, Koralov SB, Kleinridders A, Husch A, Münzberg H, Hampel B, et al: Enhanced Stat3 activation in POMC neurons provokes negative feedback inhibition of leptin and insulin signaling in obesity. J Neurosci. 29:11582–11593. 2009.PubMed/NCBI View Article : Google Scholar
7	American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care. 43 (Suppl 1):S14–S31. 2020.PubMed/NCBI View Article : Google Scholar
8	Margetic S, Gazzola C, Pegg GG and Hill RA: Leptin: A review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 26:1407–1433. 2002.PubMed/NCBI View Article : Google Scholar
9	Myers MG Jr, Leibel RL, Seeley RJ and Schwartz MW: Obesity and leptin resistance: Distinguishing cause from effect. Trends Endocrinol Metab. 21:643–651. 2010.PubMed/NCBI View Article : Google Scholar
10	Ikejima K, Okumura K, Lang T, Honda H, Abe W, Yamashina S, Enomoto N, Takei Y and Sato N: The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res. 33:151–154. 2005.PubMed/NCBI View Article : Google Scholar
11	Moonishaa TM, Nanda SK, Shamraj M, Sivaa R, Sivakumar P and Ravichandran K: Evaluation of leptin as a marker of insulin resistance in type 2 diabetes mellitus. Int J Appl Basic Med Res. 7:176–180. 2017.PubMed/NCBI View Article : Google Scholar
12	Tiwari-Heckler S, Gan-Schreier H, Stremmel W, Chamulitrat W and Pathil A: Circulating phospholipid patterns in NAFLD patients associated with a combination of metabolic risk factors. Nutrients. 10(649)2018.PubMed/NCBI View Article : Google Scholar
13	Lustig RH, Sen S, Soberman JE and Velasquez-Mieyer PA: Obesity, leptin resistance, and the effects of insulin reduction. Int J Obes Relat Metab Disord. 28:1344–1348. 2004.PubMed/NCBI View Article : Google Scholar
14	Paz-Filho G, Mastronardi C, Wong ML and Licinio J: Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab. 16 (Suppl 3):S549–S555. 2012.PubMed/NCBI View Article : Google Scholar
15	Popa AR, Bungau S, Vesa CM, Bondar AC, Pantis C, Maghiar O, Dimulescu IA, Nistor-Cseppento DC and Rus M: Evaluating the efficacy of the treatment with benfotiamine and alpha-lipoic acid in distal symmetric painful diabetic polyneuropathy. Rev Chim. 70:3108–3114. 2019.
16	Moisi IM, Rus M, Bungau S, Zaha CD, Uivarosan D, Fratila O, Tit DM, Endres L, Nistor-Cseppento DC and Popescu MI: Acute coronary syndromes in chronic kidney disease: Clinical and therapeutic characteristics. Medicina (Kaunas). 56(118)2020.PubMed/NCBI View Article : Google Scholar
17	Misra VL, Khashab M and Chalasani N: Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 11:50–55. 2009.
18	Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM and Park SK: Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 29:1926–1931. 2014.PubMed/NCBI View Article : Google Scholar
19	Adolph TE, Grander C, Grabherr F and Tilg H: Adipokines and non-alcoholic fatty liver disease, multiple interactions. Int J Mol Sci. 18(1649)2017.PubMed/NCBI View Article : Google Scholar
20	Lee Y, Kwon EY and Choi MS: Dietary isoliquiritigenin at a low dose ameliorates insulin resistance and NAFLD in diet-induced obesity in C57BL/6J mice. Int J Mol Sci. 19(3281)2018.PubMed/NCBI View Article : Google Scholar
21	Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F and Petta S: Drugs in NAFLD: The accomplishment of two goals at once? Pharmaceuticals (Basel). 11(121)2018.PubMed/NCBI View Article : Google Scholar
22	Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA and Saxena NK: Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 52:1713–22. 2010.PubMed/NCBI View Article : Google Scholar
23	Diaconu C, Salmen T, Gaman MA, Bratu OG, Mischianu D, Marcu RD, Suceveanu AI, Costache RS and Pantea Stoian A: SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: Which are the benefits? Rom J Mil Med. 122:16–21. 2019.